SEC Form 25-NSE filed by Apellis Pharmaceuticals Inc.
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
| UNITED STATES |
|
||||||||||||||||||||||||||||||
| SECURITIES AND EXCHANGE COMMISSION | |||||||||||||||||||||||||||||||
| Washington, D.C. 20549 | |||||||||||||||||||||||||||||||
| FORM 25 | |||||||||||||||||||||||||||||||
|
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. | |||||||||||||||||||||||||||||||
| Commission File Number | 001-38276 | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration: | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person. | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | |||||||||||||||||||||||||||||||